* Keros Therapeutics Inc reported a quarterly adjusted loss of $1.25 per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $-1.27. The mean expectation of twelve analysts for the quarter was for a loss of $1.23 per share. Wall Street expected results to range from $-1.43 to $-1.10 per share.
* Revenue was $37.00 thousand; analysts expected zero.
* Keros Therapeutics Inc's reported EPS for the quarter was a loss of $1.25.
* The company reported a quarterly loss of $45.26 million.
* Keros Therapeutics Inc shares had risen by 6.7% this quarter and gained 22.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 6.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Keros Therapeutics Inc is $88.00 This summary was machine generated from LSEG data August 7 at 09:42 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -1.23 -1.25 Missed
Mar. 31 2024 -1.35 -1.21 Beat
Dec. 31 2023 -1.37 -1.34 Beat
Sep. 30 2023 -1.35 -1.33 Beat
Comments